EUVIMEDDescubrir EUVIMED
Open access · CC BY 4.0

A Bayesian Hierarchical Mixture Cure Modelling Framework to Utilize Multiple Survival Datasets for Long‐Term Survivorship Estimates: A Case Study From Previously Untreated Metastatic Melanoma

Nathan Green, Murat Kurt, Andriy Moshyk, James Larkin, Gianluca Baio

Statistics in Medicine · 2025-06 · 44 (13-14)

DOI: 10.1002/sim.70132 ↗

At a glance

Journal article in Statistics in Medicine, published online on 2025-05-30. Written by Nathan Green and 4 co-authors. Institution: Department of Statistical Science, UCL, London, UK. Major MEDLINE topics: Melanoma, Models, Statistical. Cited 4 times so far (Crossref); 35 references. The full text is freely available (open access, CC BY 4.0).

ResumenSubjectsDatos bibliográficosCiteRelated studies

Abstract (original language)

Time to an event of interest over a lifetime is a central measure of the clinical benefit of an intervention used in a health technology assessment (HTA). Within the same trial, multiple end‐points may also be considered. For example, overall and progression‐free survival time for different drugs in oncology studies. A common challenge is when an intervention is only effective for some proportion of the population who are not clinically identifiable. Therefore, latent group membership as well as separate survival models for identified groups need to be estimated. However, follow‐up in trials may be relatively short leading to substantial censoring. We present a general Bayesian hierarchical framework that can handle this complexity by exploiting the similarity of cure fractions between end‐points; accounting for the correlation between them and improving the extrapolation beyond the observed data. Assuming exchangeability between cure fractions facilitates the borrowing of information between end‐points. We undertake a comprehensive simulation study to evaluate the model performance under different scenarios. We also show the benefits of using our approach with a motivating example, the CheckMate 067 phase 3 trial consisting of patients with metastatic melanoma treated with first line therapy.

Subjects

MeSH terms (MEDLINE)

MelanomaModels, StatisticalBayes TheoremHumansComputer SimulationSurvival AnalysisClinical Trials, Phase III as TopicNeoplasm MetastasisSkin Neoplasms

Author keywords

extrapolationmulti‐level modeloncologysurvival analysis

Authors and institutions

  • Department of Statistical Science, UCL, London, UK.
  • Worldwide Health Economics and Outcomes Research, Bristol Myers Squibb, Lawrence, New Jersey, USA.
  • The Royal Marsden Hospital, London, UK.

Cite

APA

Green, N., Kurt, M., Moshyk, A., Larkin, J., & Baio, G. (2025). A Bayesian Hierarchical Mixture Cure Modelling Framework to Utilize Multiple Survival Datasets for Long‐Term Survivorship Estimates: A Case Study From Previously Untreated Metastatic Melanoma. Statistics in Medicine, 44(13-14). https://doi.org/10.1002/sim.70132

Vancouver

Green N, Kurt M, Moshyk A, Larkin J, Baio G. A Bayesian Hierarchical Mixture Cure Modelling Framework to Utilize Multiple Survival Datasets for Long‐Term Survivorship Estimates: A Case Study From Previously Untreated Metastatic Melanoma. Statistics in Medicine. 2025;44(13-14). doi:10.1002/sim.70132

BibTeX
@article{Green2025,
  author = {Green, Nathan and Kurt, Murat and Moshyk, Andriy and Larkin, James and Baio, Gianluca},
  title = {A Bayesian Hierarchical Mixture Cure Modelling Framework to Utilize Multiple Survival Datasets for Long‐Term Survivorship Estimates: A Case Study From Previously Untreated Metastatic Melanoma},
  journal = {Statistics in Medicine},
  year = {2025},
  volume = {44},
  number = {13-14},
  doi = {10.1002/sim.70132}
}
Start for free →